Erratum: Virus-like glycodendrinanoparticles displaying quasi-equivalent nested polyvalency upon glycoprotein platforms potently block viral infection (Nature Communications (2012) 3 (1303) DOI: 10.1038/ncomms2302);Virus-like glycodendrinanoparticles displaying quasi-equivalent nested polyvalency upon glycoprotein platforms potently block viral infection

Nature Communications

Volumn 3, Issue , 2012, Pages

  Ribeiro Viana, Renato ^a,b   Sánchez Navarro, MacArena ^a   Luczkowiak, Joanna ^c   Koeppe, Julia R ^a   Delgado, Rafael ^c   Rojo, Javier ^b   Davis, Benjamin G ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF SEVILLE   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD209 ANTIGEN; DENDRIMER; GLYCAN; GLYCOPROTEIN;

DIAMETER; HEALTH CARE; INFECTIOUS DISEASE; LIGAND; PATHOGEN; PROTEIN; VIRAL DISEASE;

ARTICLE; CHEMICAL INTERACTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EBOLA VIRUS; HUMAN; HUMAN CELL; MOLECULAR MIMICRY; NONHUMAN; PARTICLE SIZE; T LYMPHOCYTE; VIRUS INFECTION; VIRUS PARTICLE;

EBOLA VIRUS;

EID: 84871740148     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms2457     Document Type: Erratum

References (53)

1. Neyrolles, O., Gicquel, B. & Quintana-Murci, L. Towards a crucial role for DCSIGN in tuberculosis and beyond. Trends Microbiol. 14, 383-387 (2006).
2. Gordon, S. Pattern recognition receptors: doubling up for the innate immune response. Cell 111, 927-930 (2002).
3. Medzhitov, R. Recognition of microorganisms and activation of the immune response. Nature 449, 819-826 (2007).
4. Geijtenbeek, T. B. H. et al. Identification of DC-SIGN, a novel dendritic cell specific ICAM-3 receptor that supports primary immune responses. Cell 100, 575-585 (2000).
5. Guo, Y. et al. Structural basis for distinct ligand-binding and targeting properties of the receptors DC-SIGN and DC-SIGNR. Nat. Struct. Mol. Biol. 11, 591-598 (2004).
6. Steinman, R. M. DC-SIGN: a guide to some mysteries of dendritic cells. Cell 100, 491-494 (2000).
7. van, K. Y. & Geijtenbeek, T. B. H. DC-SIGN: escape mechanism for pathogens. Nat. Rev. Immunol. 3, 697-709 (2003).
8. Arce, E. et al. Glycodendritic structures based on Boltorn hyperbranched polymers and their interactions with Lens culinaris lectin. Bioconjugate Chem. 14, 817-823 (2003).
9. Lasala, F., Arce, E., Otero, J. R., Rojo, J. & Delgado, R. Mannosyl glycodendritic structure inhibits DC-SIGN-mediated ebola virus infection in cis and in trans. Antimicrob. Agents Chemother. 47, 3970-3972 (2003).
10. Borrok, M. J. & Kiessling, L. L. Non-carbohydrate inhibitors of the lectin DCSIGN. J. Am. Chem. Soc. 129, 12780-12785 (2007).
11. Reina, J. J. et al. 1,2-Mannobioside mimic: synthesis, DC-SIGN interaction by NMR and docking, and antiviral activity. ChemMedChem 2, 1030-1036 (2007).
12. Mitchell, D. A. et al. Synthesis 2-C-branched derivatives of D-mannose: 2-Caminomethyl- D-mannose binds to the human C-type lectin DC-SIGN with affinity greater than an order of magnitude compared to that of D-mannose. Tetrahedron Asymmetry 18, 1502-1510 (2007).
13. Martínez-Á vila, O. et al. Multivalent manno- glyconanoparticles inhibit DCSIGN- mediated HIV-1 trans-infection of human T cells. ChemBioChem 10, 1806-1809 (2009).
14. Martínez-Á vila, O. et al. Gold manno-glyconanoparticles: multivalent systems to block HIV-1 gp120 binding to the lectin DC-SIGN. Chem. Eur. J. 15, 9874-9888 (2009).
15. Sattin, S. et al. Inhibition of DC-SIGN-mediated HIV infection by a linear trimannoside mimic in a tetravalent presentation. ACS Chem. Biol. 5, 301-312 (2010).
16. Sanchez-Navarro, M. & Rojo, J. Targeting DC-SIGN wih carbohydrate multivalent systems. Drug News Perspect. 23, 557-572 (2010).
17. Wang, S.-K. et al. Targeting the carbohydrates on HIV-1: interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc. Natl Acad. Sci. USA 105, 3690-3695 (2008).
18. Greatrex, B. W. et al. The synthesis and immune stimulating action of mannose-capped lysine-based dendrimers. Tetrahedron 65, 2939-2950 (2009).
19. Luczkowiak, J. et al. Pseudosaccharide functionalized dendrimers as potent inhibitors of DC-SIGN dependent Ebola pseudotyped viral infection. Bioconjugate Chem. 22, 1354-1365 (2011).
20. Andreini, M. et al. Second generation of fucose-based DC-SIGN ligands: affinity improvement and specificity versus Langerin. Org. Biomol. Chem. 9, 5778-5786 (2011).
21. Prost, L. R., Grim, J. C., Tonelli, M. & Kiessling, L. L. Noncarbohydrate glycomimetics and glycoprotein surrogates as DC-SIGN antagonists and agonists. ACS Chem. Biol. 7, 1603-1608 (2012).
22. André, S., Ortega, P. J. C., Perez, M. A., Roy, R. & Gabius, H.-J. Lactosecontaining starburst dendrimers: influence of dendrimer generation and binding-site orientation of receptors (plant/animal lectins and immunoglobulins) on binding properties. Glycobiology 9, 1253-1261 (1999).
23. Camponovo, J. et al. 'Click' glycodendrimers containing 27, 81, and 243 modified xylopyranoside termini. J. Org. Chem. 74, 5071-5074 (2009).
24. Davis, B. G. The controlled glycosylation of a protein with a bivalent glycan: towards a new class of glycoconjugates, glycodendriproteins. Chem. Commun. 351-352 (2001).
25. Rendle, P. M. et al. Glycodendriproteins: a synthetic glycoprotein mimic enzyme with branched sugar-display potently inhibits bacterial aggregation. J. Am. Chem. Soc. 126, 4750-4751 (2004).
26. Robinson, M. A. et al. LEAPT: lectin-directed enzyme-activated prodrug therapy. Proc. Natl Acad. Sci. USA 101, 14527-14532 (2004).
27. Chalker, J. M., Bernardes, G. J. L. & Davis, B. G. A 'tag-and-modify' approach to site-selective protein modification. Acc. Chem. Res. 44, 730-741 (2011).
28. Sato, M. et al. Glycoinsulins: dendritic sialyloligosaccharide-displaying insulins showing a prolonged blood-sugar-lowering activity. J. Am. Chem. Soc. 126, 14013-14022 (2004).
29. Ni, J., Song, H., Wang, Y., Stamatos, N. M. & Wang, L. -X. Toward a carbohydrate-based HIV-1 vaccine: synthesis and immunological studies of oligomannose-containing glycoconjugates. Bioconjugate Chem. 17, 493-500 (2006).
30. Kostiainen, M. A., Szilvay, G. R., Smith, D. K., Linder, M. B. & Ikkala, O. Multivalent dendrons for high-affinity adhesion of proteins to DNA. Angew. Chem. Int. Ed. 45, 3538-3542 (2006).
31. Crick, F. H. C. & Watson, J. D. The structure of small viruses. Nature 177, 473-475 (1956).
32. Caspar, D. L. D. & Klug, A. Physical principles in the construction of regular viruses. Cold Spring Harbor Symp. Quant. Biol. 27, 1-24 (1962).
33. Johnson, J. E. & Speir, J. A. Quasi-equivalent viruses: a paradigm for protein assemblies. J. Mol. Biol. 269, 665-675 (1997).
34. Kozlovska, T. M. et al. Recombinant RNA phage Qb capsid particles synthesized and self-assembled in Escherichia coli. Gene 137, 133-137 (1993).
35. Strable, E. et al. Unnatural amino acid incorporation into virus-like particles. Bioconjugate Chem. 19, 866-875 (2008).
36. Astronomo, R. et al. Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds. Chem. Biol. 17, 357-370 (2010).
37. Doores, K. J. et al. A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity. Proc. Natl Acad. Sci. USA 107, 17107-17112 (2010).
38. Tornøe, C. W., Christensen, C. & Meldal, M. Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. J. Org. Chem. 67, 3057-3064 (2002).
39. Rostovtsev, V. V., Green, L. G., Fokin, V. V. & Sharpless, K. B. A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective 'ligation' of azides and terminal alkynes. Angew. Chem. Int. Ed. 41, 2596-2599 (2002).
40. Ortega-Munoz, M., Lopez-Jaramillo, J., Hernandez-Mateo, F. & Santoyo- Gonzalez, F. Synthesis of glyco-silicas by Cu(I)-catalyzed 'click-chemistry' and their applications in affinity chromatography. Adv. Synth. Catal. 348, 2410-2420 (2006).
41. Van, H. J. C. M., Kiick, K. L. & Tirrell, D. A. Efficient incorporation of unsaturated methionine analogues into proteins in vivo. J. Am. Chem. Soc. 122, 1282-1288 (2000).
42. van Kasteren, S. I., Kramer, H. B., Gamblin, D. P. & Davis, B. G. Siteselective glycosylation of proteins: creating synthetic glycoproteins. Nat. Protoc. 2, 3185-3194 (2007).
43. van Kasteren, S. I. et al. Expanding the diversity of chemical protein modification allows post-translational mimicry. Nature 446, 1105-1109 (2007).
44. Alvarez, C. P. et al. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J. Virol. 76, 6841-6844 (2002).
45. Yang, Z.-y. et al. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science 279, 1034-1037 (1998).
46. Mammen, M., Choi, S.-K. & Whitesides, G. M. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Ed. 37 (1998).
47. Golmohammadi, R., Fridborg, K., Bundule, M., Valegard, K. & Liljas, L. The crystal structure of bacteriophage Q beta at 3.5 A resolution. Structure 4, 543 (1996).
48. Tabarani, G. et al. DC-SIGN neck domain is a pH-sensor controlling oligomerization. J. Biol. Chem. 284, 21229-21240 (2009).
49. de Bakker, B. I. et al. Nanoscale organization of the pathogen receptor DCSIGN mapped by single-molecule high-resolution fluorescence microscopy. ChemPhysChem 8, 1473-1480 (2007).
50. He, J. et al. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J. Virol. 69, 6705-6711 (1995).
51. Yang, S. et al. Generation of retroviral vector for clinical studies using transient transfection. Hum. Gene Ther. 10, 123-132 (1999).
52. Puig-Kroger, A. et al. Maturation-dependent expression and function of the CD49d integrin on monocyte-derived human dendritic cells. J. Immunol. 165, 4338-4345 (2000).
53. Relloso, M. et al. DC-SIGN (CD209) expression is IL-4 dependent and is negatively regulated by IFN, TGF-b, and anti-inflammatory agents. J. Immunol. 168, 2634-2643 (2002).